Green Cross Corp Total Liabilities
Green Cross Corp total liabilities. Based on the latest financial reports, Green Cross Corp (006280) has total liabilities worth ₩1.70 Trillion KRW (≈ $1.15 Billion USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Green Cross Corp (006280) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Green Cross Corp (2003–2024)
Total liabilities of Green Cross Corp from 2003 to 2024. This chart illustrates how Green Cross Corp's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of Green Cross Corp to see how much of total assets are deployed in long-term investments.
Green Cross Corp Competitors by Total Liabilities
The table below lists competitors of Green Cross Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
MYT Netherlands Parent BV
NYSE:MYTE
|
USA | $280.60 Million |
|
Guangxi Liuzhou Pharm Co Ltd
SHG:603368
|
China | CN¥13.05 Billion |
|
Bank Pan Indonesia Tbk
JK:PNBN
|
Indonesia | Rp172.19 Trillion |
|
Guanglian Aviation Industry Co Ltd
SHE:300900
|
China | CN¥3.01 Billion |
|
HNA Technology Co Ltd A
SHG:600751
|
China | CN¥2.30 Billion |
|
Aerosun Corp
SHG:600501
|
China | CN¥2.76 Billion |
|
Zhejiang Songyuan Automotive Safety
SHE:300893
|
China | CN¥1.74 Billion |
|
Paradise Co. Ltd
KQ:034230
|
Korea | ₩1.78 Trillion |
Liability Composition Analysis (2003–2024)
This chart breaks down Green Cross Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 006280 asset base.
Liquidity & Leverage Metrics
Green Cross Corp Total Liabilities Ratios Explained
Green Cross Corp total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.18 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.53 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Green Cross Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Green Cross Corp (2003–2024)
The table below shows the annual total liabilities of Green Cross Corp from 2003 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩1.26 Trillion ≈ $855.82 Million |
+14.45% |
| 2023-12-31 | ₩1.10 Trillion ≈ $747.79 Million |
+15.08% |
| 2022-12-31 | ₩958.90 Billion ≈ $649.83 Million |
-0.36% |
| 2021-12-31 | ₩962.39 Billion ≈ $652.20 Million |
+9.10% |
| 2020-12-31 | ₩882.09 Billion ≈ $597.78 Million |
+13.79% |
| 2019-12-31 | ₩775.22 Billion ≈ $525.36 Million |
+29.81% |
| 2018-12-31 | ₩597.20 Billion ≈ $404.72 Million |
+0.39% |
| 2017-12-31 | ₩594.87 Billion ≈ $403.13 Million |
+21.01% |
| 2016-12-31 | ₩491.60 Billion ≈ $333.15 Million |
+17.77% |
| 2015-12-31 | ₩417.42 Billion ≈ $282.88 Million |
+1.88% |
| 2014-12-31 | ₩409.72 Billion ≈ $277.66 Million |
+54.70% |
| 2013-12-31 | ₩264.86 Billion ≈ $179.49 Million |
-1.59% |
| 2012-12-31 | ₩269.15 Billion ≈ $182.40 Million |
+16.98% |
| 2011-12-31 | ₩230.07 Billion ≈ $155.92 Million |
+15.58% |
| 2010-12-31 | ₩199.07 Billion ≈ $134.90 Million |
+12.66% |
| 2006-12-31 | ₩176.70 Billion ≈ $119.75 Million |
+16.99% |
| 2005-12-31 | ₩151.03 Billion ≈ $102.35 Million |
+6.48% |
| 2004-12-31 | ₩141.84 Billion ≈ $96.12 Million |
+169.88% |
| 2003-12-31 | ₩52.56 Billion ≈ $35.62 Million |
-- |
About Green Cross Corp
GC Biopharma Corp., a biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea and internationally. It provides over-the-counter drugs, such as Acustop Cataplasma for Analgesic and anti-inflammatory effect; Kenhancer plaster for anti-inflammatory; and Zenol Cool Type and Zenol Mild Hot Type drugs to treat anti-inflammatory and pain relief. The company also offers Albumin-… Read more